| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Bacteremia | 17 | 2019 | 1372 | 3.46 | Why? |
| Community-Acquired Infections | 13 | 2019 | 2328 | 2.47 | Why? |
| Taiwan | 54 | 2021 | 2556 | 2.41 | Why? |
| Proteus Infections | 2 | 2017 | 9 | 1.43 | Why? |
| Clostridium Infections | 4 | 2019 | 595 | 1.34 | Why? |
| Anti-Bacterial Agents | 22 | 2021 | 10083 | 1.32 | Why? |
| Escherichia coli Infections | 4 | 2018 | 348 | 1.30 | Why? |
| Klebsiella Infections | 5 | 2017 | 466 | 1.23 | Why? |
| Drug Therapy | 2 | 2019 | 280 | 1.20 | Why? |
| Levofloxacin | 3 | 2019 | 115 | 1.09 | Why? |
| Severe Dengue | 4 | 2019 | 135 | 1.05 | Why? |
| Enterobacteriaceae Infections | 5 | 2019 | 529 | 0.97 | Why? |
| Dengue | 5 | 2018 | 1565 | 0.82 | Why? |
| beta-Lactamases | 5 | 2017 | 759 | 0.71 | Why? |
| Infection Control Practitioners | 1 | 2017 | 50 | 0.67 | Why? |
| Typhus, Endemic Flea-Borne | 2 | 2017 | 25 | 0.66 | Why? |
| Diarrhea | 3 | 2019 | 2743 | 0.60 | Why? |
| Legionella pneumophila | 1 | 2016 | 143 | 0.59 | Why? |
| Legionnaires' Disease | 1 | 2016 | 108 | 0.58 | Why? |
| Professional Competence | 1 | 2017 | 246 | 0.52 | Why? |
| Klebsiella pneumoniae | 5 | 2018 | 658 | 0.51 | Why? |
| Escherichia coli | 5 | 2018 | 1547 | 0.51 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.49 | Why? |
| Case Management | 1 | 2015 | 285 | 0.48 | Why? |
| Vancomycin Resistance | 1 | 2012 | 55 | 0.47 | Why? |
| Enterococcus | 1 | 2012 | 73 | 0.46 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 5 | 2018 | 711 | 0.46 | Why? |
| Patient Care Bundles | 3 | 2017 | 137 | 0.45 | Why? |
| Proteus mirabilis | 2 | 2017 | 11 | 0.36 | Why? |
| Cross Infection | 9 | 2019 | 8675 | 0.36 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2012 | 323 | 0.36 | Why? |
| Staphylococcal Infections | 4 | 2018 | 1099 | 0.35 | Why? |
| HIV Infections | 7 | 2018 | 11620 | 0.34 | Why? |
| Fasciitis, Necrotizing | 2 | 2018 | 56 | 0.33 | Why? |
| Dengue Virus | 3 | 2019 | 910 | 0.32 | Why? |
| Microbial Sensitivity Tests | 11 | 2019 | 2886 | 0.31 | Why? |
| Immunoassay | 2 | 2020 | 4485 | 0.31 | Why? |
| Cephalosporins | 2 | 2019 | 250 | 0.31 | Why? |
| Blood Culture | 3 | 2018 | 308 | 0.30 | Why? |
| Enterobacteriaceae | 3 | 2018 | 395 | 0.30 | Why? |
| Bacterial Toxins | 3 | 2018 | 185 | 0.29 | Why? |
| Aged | 40 | 2021 | 215776 | 0.29 | Why? |
| Aged, 80 and over | 23 | 2019 | 88759 | 0.29 | Why? |
| Coinfection | 4 | 2021 | 6820 | 0.29 | Why? |
| Bacterial Infections | 4 | 2021 | 2229 | 0.28 | Why? |
| Continuity of Patient Care | 1 | 2015 | 1574 | 0.28 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.27 | Why? |
| Male | 49 | 2021 | 367725 | 0.27 | Why? |
| Retrospective Studies | 24 | 2021 | 105322 | 0.26 | Why? |
| Drug Resistance, Multiple, Bacterial | 4 | 2018 | 1115 | 0.26 | Why? |
| Female | 47 | 2021 | 380317 | 0.26 | Why? |
| Candidemia | 2 | 2018 | 353 | 0.26 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.26 | Why? |
| Catheter-Related Infections | 2 | 2017 | 381 | 0.25 | Why? |
| Adenosine Monophosphate | 2 | 2020 | 5652 | 0.25 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.25 | Why? |
| Candida | 2 | 2017 | 425 | 0.25 | Why? |
| Middle Aged | 38 | 2020 | 270681 | 0.25 | Why? |
| Aeromonas | 2 | 2018 | 6 | 0.25 | Why? |
| Pseudomonas Infections | 3 | 2017 | 425 | 0.24 | Why? |
| Tertiary Care Centers | 3 | 2016 | 8248 | 0.24 | Why? |
| CD4 Lymphocyte Count | 3 | 2017 | 1517 | 0.24 | Why? |
| Environmental Microbiology | 2 | 2018 | 575 | 0.24 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.24 | Why? |
| Anti-HIV Agents | 5 | 2017 | 2209 | 0.23 | Why? |
| Humans | 83 | 2021 | 930598 | 0.23 | Why? |
| Endocarditis, Bacterial | 2 | 2017 | 344 | 0.23 | Why? |
| Caenorhabditis elegans | 2 | 2018 | 82 | 0.23 | Why? |
| Viral Nonstructural Proteins | 2 | 2018 | 4810 | 0.22 | Why? |
| Pseudomonas aeruginosa | 4 | 2018 | 652 | 0.22 | Why? |
| Antigens, Viral | 1 | 2018 | 6298 | 0.22 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.22 | Why? |
| Macau | 1 | 2020 | 116 | 0.21 | Why? |
| Gram-Negative Bacterial Infections | 2 | 2018 | 398 | 0.20 | Why? |
| Adult | 31 | 2021 | 244371 | 0.20 | Why? |
| beta-Lactams | 3 | 2018 | 210 | 0.20 | Why? |
| Survival Analysis | 3 | 2019 | 7592 | 0.20 | Why? |
| Gram-Negative Bacteria | 2 | 2017 | 473 | 0.20 | Why? |
| Mycobacterium abscessus | 1 | 2019 | 31 | 0.19 | Why? |
| Urinary Tract Infections | 2 | 2017 | 534 | 0.19 | Why? |
| HIV Seroprevalence | 1 | 2018 | 16 | 0.19 | Why? |
| Streptococcus | 1 | 2018 | 76 | 0.19 | Why? |
| Long-Term Care | 4 | 2020 | 2047 | 0.19 | Why? |
| DNA-Directed RNA Polymerases | 1 | 2020 | 239 | 0.19 | Why? |
| Caenorhabditis elegans Proteins | 1 | 2018 | 28 | 0.18 | Why? |
| Bacterial Proteins | 4 | 2017 | 1318 | 0.18 | Why? |
| Thiazolidinediones | 1 | 2018 | 70 | 0.18 | Why? |
| Time Factors | 4 | 2019 | 31397 | 0.18 | Why? |
| Salmonella | 1 | 2018 | 58 | 0.18 | Why? |
| Hepatitis A Antibodies | 1 | 2017 | 18 | 0.18 | Why? |
| Streptococcus pneumoniae | 2 | 2021 | 827 | 0.18 | Why? |
| Receptors, Purinergic P2X7 | 1 | 2018 | 35 | 0.18 | Why? |
| Aggregatibacter aphrophilus | 1 | 2017 | 3 | 0.18 | Why? |
| Oxazolidinones | 2 | 2021 | 49 | 0.18 | Why? |
| Pasteurellaceae Infections | 1 | 2017 | 9 | 0.18 | Why? |
| Odds Ratio | 3 | 2019 | 5861 | 0.18 | Why? |
| Klebsiella | 1 | 2017 | 35 | 0.18 | Why? |
| Pseudomonas | 1 | 2017 | 65 | 0.18 | Why? |
| Electrophoresis | 1 | 2017 | 35 | 0.17 | Why? |
| Mitral Valve Annuloplasty | 1 | 2017 | 35 | 0.17 | Why? |
| Penicillin Resistance | 1 | 2016 | 15 | 0.17 | Why? |
| Adolescent | 13 | 2020 | 86841 | 0.17 | Why? |
| Escherichia coli Proteins | 1 | 2018 | 168 | 0.17 | Why? |
| Proportional Hazards Models | 5 | 2018 | 6543 | 0.17 | Why? |
| Endophthalmitis | 1 | 2019 | 105 | 0.17 | Why? |
| Young Adult | 16 | 2020 | 93724 | 0.17 | Why? |
| Risk Factors | 13 | 2021 | 71621 | 0.17 | Why? |
| Hepatitis A virus | 1 | 2017 | 68 | 0.17 | Why? |
| Salmonella enterica | 1 | 2016 | 39 | 0.17 | Why? |
| AIDS Dementia Complex | 1 | 2017 | 48 | 0.17 | Why? |
| Olfactory Bulb | 1 | 2020 | 333 | 0.16 | Why? |
| Livestock | 1 | 2018 | 184 | 0.16 | Why? |
| Antifungal Agents | 2 | 2017 | 1828 | 0.16 | Why? |
| Propensity Score | 4 | 2018 | 2690 | 0.16 | Why? |
| Fosfomycin | 1 | 2016 | 48 | 0.16 | Why? |
| False Positive Reactions | 2 | 2020 | 1338 | 0.16 | Why? |
| Scrub Typhus | 1 | 2017 | 68 | 0.16 | Why? |
| Intraabdominal Infections | 1 | 2017 | 90 | 0.16 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2017 | 170 | 0.16 | Why? |
| Drug Resistance, Microbial | 1 | 2021 | 419 | 0.16 | Why? |
| Carbapenems | 2 | 2017 | 343 | 0.15 | Why? |
| Cohort Studies | 7 | 2019 | 36005 | 0.15 | Why? |
| Interferon-gamma Release Tests | 1 | 2018 | 253 | 0.15 | Why? |
| Salmonella Infections | 1 | 2016 | 82 | 0.15 | Why? |
| Abscess | 1 | 2018 | 234 | 0.15 | Why? |
| Communicable Diseases | 2 | 2021 | 2148 | 0.15 | Why? |
| Emergency Service, Hospital | 3 | 2017 | 14232 | 0.15 | Why? |
| Q Fever | 1 | 2017 | 130 | 0.15 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2017 | 309 | 0.15 | Why? |
| Adenosine Triphosphate | 1 | 2018 | 294 | 0.15 | Why? |
| MAP Kinase Signaling System | 1 | 2018 | 360 | 0.15 | Why? |
| Anti-Infective Agents | 2 | 2017 | 1766 | 0.15 | Why? |
| Prothrombin Time | 1 | 2017 | 434 | 0.15 | Why? |
| Rifampin | 1 | 2017 | 276 | 0.15 | Why? |
| Luminescent Measurements | 1 | 2020 | 924 | 0.15 | Why? |
| Partial Thromboplastin Time | 1 | 2017 | 436 | 0.14 | Why? |
| Administration, Intravenous | 1 | 2019 | 1115 | 0.14 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.14 | Why? |
| Ceftriaxone | 1 | 2016 | 365 | 0.14 | Why? |
| Blood | 1 | 2015 | 274 | 0.14 | Why? |
| Proton Pump Inhibitors | 1 | 2019 | 377 | 0.14 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.14 | Why? |
| Treatment Outcome | 11 | 2021 | 51732 | 0.14 | Why? |
| Mycoses | 1 | 2021 | 589 | 0.14 | Why? |
| Latent Tuberculosis | 1 | 2018 | 324 | 0.13 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.13 | Why? |
| Urine | 1 | 2016 | 469 | 0.13 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.13 | Why? |
| Statistics, Nonparametric | 1 | 2017 | 1008 | 0.13 | Why? |
| Betacoronavirus | 11 | 2020 | 204454 | 0.13 | Why? |
| Liver Abscess | 2 | 2018 | 42 | 0.13 | Why? |
| Hospitalization | 4 | 2019 | 54280 | 0.13 | Why? |
| Drug Resistance, Bacterial | 4 | 2021 | 1414 | 0.13 | Why? |
| Mitral Valve | 1 | 2017 | 342 | 0.13 | Why? |
| Staphylococcus aureus | 2 | 2017 | 844 | 0.13 | Why? |
| Candidiasis | 1 | 2017 | 334 | 0.13 | Why? |
| Antimicrobial Stewardship | 2 | 2021 | 931 | 0.12 | Why? |
| Pneumonia, Pneumocystis | 1 | 2017 | 322 | 0.12 | Why? |
| Catheterization, Central Venous | 1 | 2017 | 458 | 0.12 | Why? |
| Immunocompromised Host | 3 | 2021 | 5150 | 0.12 | Why? |
| Mortality | 3 | 2018 | 7132 | 0.12 | Why? |
| Molecular Typing | 3 | 2018 | 280 | 0.12 | Why? |
| Nursing Homes | 2 | 2020 | 4155 | 0.12 | Why? |
| Age Factors | 6 | 2018 | 21039 | 0.11 | Why? |
| Daptomycin | 1 | 2012 | 64 | 0.11 | Why? |
| Incidence | 10 | 2021 | 25622 | 0.11 | Why? |
| Multivariate Analysis | 3 | 2017 | 5440 | 0.11 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.11 | Why? |
| Swine Diseases | 2 | 2018 | 1219 | 0.11 | Why? |
| Enterovirus | 1 | 2015 | 402 | 0.11 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.11 | Why? |
| Hospitals, District | 1 | 2012 | 136 | 0.11 | Why? |
| beta-Lactam Resistance | 2 | 2018 | 150 | 0.11 | Why? |
| Endocarditis | 1 | 2016 | 368 | 0.11 | Why? |
| Inflammasomes | 1 | 2018 | 710 | 0.11 | Why? |
| Linezolid | 1 | 2012 | 160 | 0.11 | Why? |
| Prevalence | 9 | 2021 | 25773 | 0.11 | Why? |
| Acetamides | 1 | 2012 | 141 | 0.11 | Why? |
| Prospective Studies | 7 | 2019 | 43301 | 0.11 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.11 | Why? |
| Enterovirus Infections | 1 | 2015 | 404 | 0.11 | Why? |
| Pneumococcal Infections | 1 | 2016 | 562 | 0.10 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.10 | Why? |
| Shock, Septic | 2 | 2017 | 1313 | 0.10 | Why? |
| Seroepidemiologic Studies | 3 | 2021 | 10017 | 0.10 | Why? |
| Picornaviridae Infections | 1 | 2015 | 544 | 0.10 | Why? |
| Thorax | 1 | 2020 | 1873 | 0.10 | Why? |
| Aspartate Aminotransferases | 1 | 2017 | 1394 | 0.10 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2017 | 861 | 0.10 | Why? |
| Logistic Models | 3 | 2019 | 9089 | 0.10 | Why? |
| Postoperative Complications | 2 | 2019 | 5861 | 0.10 | Why? |
| Rhinovirus | 1 | 2015 | 979 | 0.10 | Why? |
| Bilirubin | 1 | 2012 | 503 | 0.09 | Why? |
| Vancomycin | 1 | 2012 | 328 | 0.09 | Why? |
| Health Care Costs | 1 | 2017 | 1007 | 0.09 | Why? |
| Monitoring, Physiologic | 1 | 2020 | 1956 | 0.09 | Why? |
| Analysis of Variance | 1 | 2012 | 950 | 0.09 | Why? |
| Health Policy | 2 | 2020 | 6242 | 0.09 | Why? |
| Hospitals | 5 | 2018 | 11793 | 0.09 | Why? |
| Infection Control | 6 | 2020 | 23131 | 0.09 | Why? |
| Homes for the Aged | 1 | 2018 | 1071 | 0.09 | Why? |
| Prisons | 1 | 2017 | 980 | 0.09 | Why? |
| Hand Hygiene | 1 | 2018 | 1493 | 0.09 | Why? |
| Guideline Adherence | 2 | 2018 | 2309 | 0.09 | Why? |
| Prognosis | 5 | 2017 | 32490 | 0.09 | Why? |
| Thrombocytopenia | 1 | 2021 | 2093 | 0.09 | Why? |
| Drug Resistance, Multiple, Fungal | 2 | 2017 | 45 | 0.09 | Why? |
| Intensive Care Units | 4 | 2017 | 29594 | 0.08 | Why? |
| Integrons | 1 | 2006 | 13 | 0.08 | Why? |
| Animals | 9 | 2021 | 78931 | 0.08 | Why? |
| Ciprofloxacin | 2 | 2018 | 130 | 0.08 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.08 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.08 | Why? |
| Amikacin | 2 | 2019 | 62 | 0.08 | Why? |
| Patient Safety | 1 | 2021 | 4885 | 0.08 | Why? |
| Quality Improvement | 1 | 2018 | 2435 | 0.08 | Why? |
| Neoplasms | 3 | 2019 | 17251 | 0.07 | Why? |
| Universities | 1 | 2021 | 4374 | 0.07 | Why? |
| Sleep Wake Disorders | 1 | 2017 | 1463 | 0.07 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.07 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.07 | Why? |
| Genes, Bacterial | 1 | 2006 | 207 | 0.07 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.07 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.07 | Why? |
| Algorithms | 2 | 2019 | 7346 | 0.07 | Why? |
| Disease Outbreaks | 4 | 2020 | 27595 | 0.07 | Why? |
| Length of Stay | 2 | 2019 | 11042 | 0.07 | Why? |
| Comorbidity | 5 | 2020 | 34796 | 0.07 | Why? |
| Epidemics | 3 | 2019 | 6407 | 0.07 | Why? |
| Acinetobacter baumannii | 2 | 2018 | 378 | 0.07 | Why? |
| Blood Donors | 1 | 2017 | 2956 | 0.07 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.06 | Why? |
| Asymptomatic Infections | 2 | 2020 | 7218 | 0.06 | Why? |
| Ceftazidime | 2 | 2017 | 134 | 0.06 | Why? |
| Quarantine | 2 | 2021 | 18418 | 0.06 | Why? |
| Sex Factors | 2 | 2017 | 11014 | 0.06 | Why? |
| Severity of Illness Index | 4 | 2020 | 48226 | 0.06 | Why? |
| Pandemics | 16 | 2021 | 389249 | 0.06 | Why? |
| Caregivers | 1 | 2016 | 3112 | 0.06 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 952 | 0.06 | Why? |
| Polymerase Chain Reaction | 3 | 2017 | 6740 | 0.06 | Why? |
| Influenza, Human | 3 | 2021 | 10779 | 0.06 | Why? |
| Aminoglycosides | 1 | 2021 | 94 | 0.05 | Why? |
| Aging | 1 | 2017 | 3581 | 0.05 | Why? |
| Tetracyclines | 1 | 2021 | 82 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.05 | Why? |
| Immunity, Innate | 1 | 2018 | 6570 | 0.05 | Why? |
| Hospitals, University | 1 | 2012 | 4173 | 0.05 | Why? |
| Teicoplanin | 1 | 2021 | 191 | 0.05 | Why? |
| Compliance | 1 | 2018 | 28 | 0.05 | Why? |
| Longitudinal Studies | 1 | 2015 | 9893 | 0.05 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 2018 | 78 | 0.05 | Why? |
| Swine | 2 | 2018 | 3352 | 0.05 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.05 | Why? |
| Serogroup | 1 | 2021 | 510 | 0.05 | Why? |
| Virginiamycin | 1 | 2018 | 5 | 0.05 | Why? |
| Erythromycin | 1 | 2018 | 17 | 0.05 | Why? |
| Tetracycline Resistance | 1 | 2017 | 8 | 0.05 | Why? |
| Tetrazoles | 1 | 2021 | 262 | 0.05 | Why? |
| DNA, Bacterial | 2 | 2017 | 835 | 0.05 | Why? |
| RNA, Ribosomal, 28S | 1 | 2017 | 13 | 0.05 | Why? |
| Dihydropteroate Synthase | 1 | 2017 | 8 | 0.05 | Why? |
| Fever | 3 | 2021 | 7795 | 0.05 | Why? |
| Leukocidins | 1 | 2018 | 47 | 0.04 | Why? |
| Mycological Typing Techniques | 1 | 2017 | 38 | 0.04 | Why? |
| Antibodies, Anti-Idiotypic | 1 | 2018 | 93 | 0.04 | Why? |
| Clarithromycin | 1 | 2019 | 112 | 0.04 | Why? |
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2017 | 13 | 0.04 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.04 | Why? |
| Sulfonylurea Compounds | 1 | 2018 | 79 | 0.04 | Why? |
| Exotoxins | 1 | 2018 | 54 | 0.04 | Why? |
| Methicillin | 1 | 2017 | 73 | 0.04 | Why? |
| Bacteria | 2 | 2021 | 1897 | 0.04 | Why? |
| Clindamycin | 1 | 2018 | 59 | 0.04 | Why? |
| Masks | 1 | 2020 | 8528 | 0.04 | Why? |
| Gentamicins | 1 | 2018 | 76 | 0.04 | Why? |
| Nontuberculous Mycobacteria | 1 | 2019 | 114 | 0.04 | Why? |
| Caspase 1 | 1 | 2018 | 149 | 0.04 | Why? |
| Vitrectomy | 1 | 2019 | 160 | 0.04 | Why? |
| Candida glabrata | 1 | 2017 | 50 | 0.04 | Why? |
| Fasciotomy | 1 | 2016 | 23 | 0.04 | Why? |
| Hepatitis A Vaccines | 1 | 2017 | 52 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| Catheters | 1 | 2017 | 93 | 0.04 | Why? |
| Fungi | 1 | 2021 | 471 | 0.04 | Why? |
| Mycobacterium Infections | 1 | 2017 | 72 | 0.04 | Why? |
| Cefazolin | 1 | 2017 | 31 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Geography, Medical | 1 | 2020 | 537 | 0.04 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2021 | 782 | 0.04 | Why? |
| Minocycline | 1 | 2018 | 101 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2019 | 8207 | 0.04 | Why? |
| Hospitals, Isolation | 1 | 2020 | 300 | 0.04 | Why? |
| Mice | 2 | 2018 | 21357 | 0.04 | Why? |
| Heterosexuality | 1 | 2018 | 148 | 0.04 | Why? |
| Toll-Like Receptor 2 | 1 | 2018 | 198 | 0.04 | Why? |
| Gonorrhea | 1 | 2021 | 315 | 0.04 | Why? |
| Fluconazole | 1 | 2017 | 145 | 0.04 | Why? |
| Pneumonia | 1 | 2016 | 5652 | 0.04 | Why? |
| In Vitro Techniques | 1 | 2020 | 1027 | 0.04 | Why? |
| Echinocandins | 1 | 2017 | 139 | 0.04 | Why? |
| Electrodes | 1 | 2017 | 203 | 0.04 | Why? |
| Mycobacterium Infections, Nontuberculous | 1 | 2019 | 167 | 0.04 | Why? |
| Surveys and Questionnaires | 3 | 2020 | 43792 | 0.04 | Why? |
| Child, Preschool | 2 | 2018 | 36283 | 0.04 | Why? |
| Viral Load | 1 | 2016 | 15850 | 0.04 | Why? |
| Debridement | 1 | 2016 | 172 | 0.04 | Why? |
| Azoles | 1 | 2017 | 185 | 0.04 | Why? |
| Hepatitis A | 1 | 2017 | 140 | 0.04 | Why? |
| Drug Utilization | 1 | 2021 | 619 | 0.04 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 214 | 0.04 | Why? |
| Pneumocystis carinii | 1 | 2017 | 205 | 0.04 | Why? |
| Child | 2 | 2017 | 70012 | 0.04 | Why? |
| Spectrometry, Mass, Electrospray Ionization | 1 | 2015 | 159 | 0.04 | Why? |
| Serologic Tests | 2 | 2020 | 4359 | 0.04 | Why? |
| Farmers | 1 | 2018 | 280 | 0.03 | Why? |
| Eye | 1 | 2019 | 374 | 0.03 | Why? |
| Body Temperature | 1 | 2020 | 875 | 0.03 | Why? |
| Respiratory Tract Infections | 1 | 2015 | 6817 | 0.03 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2018 | 449 | 0.03 | Why? |
| Reference Standards | 1 | 2018 | 1163 | 0.03 | Why? |
| Salvage Therapy | 1 | 2016 | 417 | 0.03 | Why? |
| Microbial Viability | 1 | 2018 | 406 | 0.03 | Why? |
| RNA, Ribosomal, 16S | 1 | 2017 | 793 | 0.03 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.03 | Why? |
| Microscopy | 1 | 2017 | 414 | 0.03 | Why? |
| Rectum | 1 | 2017 | 495 | 0.03 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.03 | Why? |
| Ethanol | 1 | 2018 | 533 | 0.03 | Why? |
| Sexually Transmitted Diseases | 1 | 2021 | 694 | 0.03 | Why? |
| Piperacillin | 1 | 2012 | 63 | 0.03 | Why? |
| Australasia | 1 | 2012 | 89 | 0.03 | Why? |
| Wearable Electronic Devices | 1 | 2020 | 694 | 0.03 | Why? |
| Interleukin-1beta | 1 | 2018 | 992 | 0.03 | Why? |
| HIV-1 | 2 | 2018 | 3365 | 0.03 | Why? |
| Penicillanic Acid | 1 | 2012 | 58 | 0.03 | Why? |
| Neuropsychological Tests | 1 | 2017 | 954 | 0.03 | Why? |
| DNA Primers | 2 | 2007 | 1170 | 0.03 | Why? |
| Myalgia | 1 | 2017 | 1015 | 0.03 | Why? |
| National Health Programs | 1 | 2018 | 807 | 0.03 | Why? |
| Virulence | 1 | 2018 | 2172 | 0.03 | Why? |
| Metformin | 1 | 2018 | 640 | 0.03 | Why? |
| Headache | 1 | 2021 | 2257 | 0.03 | Why? |
| HIV | 1 | 2017 | 1116 | 0.03 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2017 | 2437 | 0.03 | Why? |
| Fatigue | 1 | 2021 | 2479 | 0.03 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.03 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.03 | Why? |
| New York | 1 | 2017 | 2488 | 0.02 | Why? |
| Nasal Mucosa | 1 | 2017 | 1218 | 0.02 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.02 | Why? |
| China | 3 | 2020 | 50654 | 0.02 | Why? |
| Health Facilities | 1 | 2017 | 1230 | 0.02 | Why? |
| Hepacivirus | 1 | 2018 | 1509 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Fatal Outcome | 1 | 2018 | 3438 | 0.02 | Why? |
| Commerce | 1 | 2018 | 1109 | 0.02 | Why? |
| Hand Disinfection | 1 | 2018 | 1671 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2018 | 1019 | 0.02 | Why? |
| Pharynx | 1 | 2015 | 1544 | 0.02 | Why? |
| Bacterial Capsules | 1 | 2007 | 39 | 0.02 | Why? |
| Reagent Kits, Diagnostic | 1 | 2018 | 2149 | 0.02 | Why? |
| Iran | 1 | 2020 | 5467 | 0.02 | Why? |
| Polysaccharides, Bacterial | 1 | 2007 | 59 | 0.02 | Why? |
| Serotyping | 1 | 2007 | 154 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Republic of Korea | 1 | 2020 | 5858 | 0.02 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.02 | Why? |
| Japan | 1 | 2020 | 6653 | 0.02 | Why? |
| Health Resources | 1 | 2020 | 2592 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Macrophages | 1 | 2018 | 2784 | 0.02 | Why? |
| Zoonoses | 1 | 2020 | 3034 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Carrier State | 1 | 2017 | 2100 | 0.02 | Why? |
| Asia | 1 | 2012 | 2399 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| In Situ Hybridization | 1 | 2006 | 390 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Magnetic Resonance Imaging | 1 | 2020 | 6551 | 0.02 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.02 | Why? |
| Cloning, Molecular | 1 | 2006 | 1036 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.01 | Why? |
| Outpatients | 1 | 2015 | 3417 | 0.01 | Why? |
| India | 1 | 2020 | 11875 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.01 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.01 | Why? |
| Molecular Sequence Data | 1 | 2006 | 3198 | 0.01 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.01 | Why? |
| Base Sequence | 1 | 2006 | 3581 | 0.01 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Italy | 1 | 2020 | 38444 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| Stress, Psychological | 1 | 2017 | 10231 | 0.01 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.01 | Why? |
| Health Personnel | 1 | 2018 | 29646 | 0.01 | Why? |